Status:
TERMINATED
Contribution of Nasal High Flow in Pneumology Assessed in Acid-Free Hypercapnic Acute Respiratory Failure
Lead Sponsor:
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Conditions:
Respiratory Insufficiency
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The hypothesis is that Nasal High Flow therapy for patients with Hypercapnic Acute Respiratory Failure without acidosis, in addition to standard treatment would improve the care.
Detailed Description
The aim of the PIRAHNA study is to compare patients treated with Nasal High Flow in association with conventional standard treatment versus patients treated only with conventional standard treatment. ...
Eligibility Criteria
Inclusion
- Major patient ≥ 18 years old
- Medical diagnosis of Acute Respiratory Failure less than 48 hours
- With partial pressure of carbon dioxide (PaCO2) \> 45 and pH \> 7.35 for less than 48 hours, with no indication of Non-Invasive Ventilation (NIV) placement
- Underlying terrain of known or unknown chronic respiratory pathology (may be unknown at time of diagnosis) Examples : COPD, Bronchiectasis, Pulmonary fibrosis, asthma, sequelae pathologies …
- All etiologies (infectious, cardiac decompensation, trauma, etc.)
- Having given informed consent
- Patient under a social security scheme
- Possibility to include a patient having already been included in the study but suffering from a new episode of hypercapnic non acidic Acute Respiratory Failure with a free interval of 3 months
Exclusion
- Restrictive chronic neuromuscular or kyphoscoliotic respiratory insufficiencies
- Drug-induced Acute respiratory failure
- Pneumothorax (X-ray pulmonary detachment)
- Oxygen poisoning. In this case, PaCO2 will be asset again later with the purpose to include after oxygenotherapy decrease for a target SpO2 of 92% maximum
- Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (COVII) Pneumonia
- Tracheostomy
- Prior treatment with chronic or initiated NIV just prior to treatment (e.g. Intensive Care Unit)
- Respiratory Severity Criteria for Resuscitation Management
- Agitation or non-cooperation
- Pregnancy or breastfeeding
- Person participating in other biomedical research
- Any other reason that the investigator believes may interfere with the evaluation of the study objectives
- Person under judicial protection (guardianship, curatorship)
- Person deprived of liberty by a judicial or administrative decision
Key Trial Info
Start Date :
February 27 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 24 2025
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06008587
Start Date
February 27 2024
End Date
September 24 2025
Last Update
November 24 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de Cannes
Cannes, Alpes Maritime, France, 06400
2
Centre Hospitalier Intercommunal de Toulon- La Seyne sur Mer - Hôpital Sainte Musse
Toulon, Var, France, 83100
3
Centre Hospitalier Princesse Grace
Monaco, Monaco, 98000